Novartis (NOVN) Given a CHF 78 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. set a CHF 78 target price on Novartis (VTX:NOVN) in a research note released on Monday morning, Borsen Zeitung reports. The firm currently has a sell rating on the stock.

Other equities analysts have also recently issued reports about the company. Kepler Capital Markets set a CHF 94 price target on Novartis and gave the stock a buy rating in a report on Wednesday, January 30th. Jefferies Financial Group set a CHF 105 price target on Novartis and gave the stock a buy rating in a report on Wednesday, January 30th. Goldman Sachs Group set a CHF 110 price target on Novartis and gave the stock a buy rating in a report on Thursday, January 24th. Finally, Credit Suisse Group set a CHF 86 price target on Novartis and gave the stock a neutral rating in a report on Thursday, January 31st. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company’s stock. Novartis currently has a consensus rating of Hold and an average target price of CHF 88.29.

Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Further Reading: Fundamental Analysis and Individual Investors

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.